apixaban

06/01/2015 - "Uninterrupted apixaban administration in patients undergoing AF ablation seems to be feasible and effective in preventing clinical and silent thromboembolic events without increasing the risk of major bleeding."
01/01/2014 - "When NOACs were compared with placebo for secondary prevention of VTE, they showed superior efficacy and increased bleeding except for apixaban, which showed comparable major bleeding and composite of major and clinically relevant nonmajor bleeding rates as placebo. "
04/17/2012 - "had similar efficacy with decreased bleeding; apixaban 5 mg B.I.D. "
10/01/2015 - "Based on the results of the different studies, apixaban seems to be a good alternative to conventional anticoagulation and a reasonable treatment option, though its main and most common adverse effect is bleeding. "
07/01/2015 - "The pooled risk of major bleeding was lower in the apixaban treated groups (OR 0.84; 95 % CI 0.62-1.12; p = 0.23) however this reached significant level only in subgroup analysis of trials with anticoagulant regimes in the control (OR 0.66; 95 % CI 0.51-0.87; p = 0.003). "

11/01/2014 - "We designed the ADANCE trial to observe the effects of apixaban on recurrent stroke after TIA or minor stroke. "
03/01/2010 - "AVERROES is a double-blind, double-dummy superiority trial of apixaban 5 mg twice daily (2.5 mg twice daily in selected patients) compared with ASA 81 to 324 mg once daily in patients with AF and at least 1 risk factor for stroke who have failed or are unsuitable for VKA therapy. "
11/01/2015 - "Based on the results of this analysis, apixaban can be a cost-effective alternative to other NOACs for the prevention of stroke in patients with NVAF in Greece."
11/01/2015 - "The objective of this analysis was to assess the cost effectiveness of apixaban against other NOACs for the prevention of stroke in patients with NVAF in Greece. "
09/01/2015 - "The composite outcome of ischemic + hemorrhagic stroke was reduced by dabigatran 150 mg and apixaban. "

01/01/2012 - "Safety and efficacy of apixaban in the treatment of atrial fibrillation."
02/01/2014 - "Clinical evaluation included no trials comparing apixaban with dabigatran; any indirect comparison would be risky given the poor quality of the clinical assessment of both drugs in atrial fibrillation. "
09/01/2013 - "The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial."
01/01/2010 - "Large, phase III studies testing apixaban for the prevention of vascular events in subjects with non-valvular atrial fibrillation are also ongoing."
11/25/2015 - "How to Avoid Adverse Events During Apixaban Therapy in Patients With Atrial Fibrillation."

12/01/2008 - "At present, the safety and efficacy of apixaban for the prophylaxis and treatment of venous thromboembolism is being evaluated in Phase II and Phase III trials involving nearly 25,000 patients. "
01/01/2015 - "Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study)."
12/01/2012 - "Consequently, a study was conducted to estimate the budgetary impact for the National Health System (NHS) with apixaban for prevention of venous thromboembolism (VTE) in total hip (THR) or knee (TKR) replacement. "
01/01/2012 - "In the primary prophylaxis of venous thromboembolism after orthopaedic surgery, apixaban successfully completed the ADVANCE study programme and was approved in Europe for patients undergoing elective hip or knee replacement. "
09/01/2010 - "Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose."

01/01/2014 - "Comparing indirectly BID vs QD dosing regimens resulted in hazard ratios (HR [95% confidence interval]) for stroke and systemic embolism of 0.75 (0.58-0.96) for dabigatran 150 mg BID, and 0.91 (0.73-1.13) for apixaban BID vs the QD dosing regimen. "
12/10/2013 - "The effects of apixaban were similar among patients with and without prior CAD on reducing stroke or systemic embolism and death from any cause (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.71-1.27, P for interaction=0.12; HR 0.96, 95% CI 0.81-1.13, P for interaction=0.28). "
06/01/2013 - "In conclusion, although longer-term efficacy and safety data are needed, apixaban is an important new option for use in patients with nonvalvular AF to reduce the risk of stroke or systemic embolism."
01/01/2016 - "The effect of apixaban on stroke or systemic embolism in COPD patients was consistent with its effect in the overall trial population."
01/01/2015 - "Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial."